Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023486 · ClinicalTrials.gov registry record · Phase 1
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
A Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, sponsored by Novita Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 18
- Study locations
NCT05023486: Recruiting Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, sponsored by Novita Pharmaceuticals.
NCT05023486 is a Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies that is actively recruiting participants, run by Novita Pharmaceuticals. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05023486, a Phase 1 study of Advanced or Metastatic Solid Tumor Malignancies, is actively recruiting participants, sponsored by Novita Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 18
- Study locations
Study Summary
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Conditions Studied
Interventions
- DRUG NP-G2-044 Monotherapy
- DRUG Anti-PD-1 Therapy
- DRUG NP-G2-044 Combination therapy
Study Locations (18)
California
- City of Hope - Duarte
- City of Hope Irvine Lennar - Irvine
- Hoag Memorial Hospital Presbyterian - Gynecologic Oncology Associates - Newport Beach
Arizona
- Honor Health Research Institute - Scottsdale
- University of Arizona - Cancer Center - Tucson
Ohio
- University of Cincinnati (UC) - Cancer Institute - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Virginia
- Virginia Cancer Specialists - Fairfax
- Virginia Commonwealth University - Massey Cancer Center - Richmond
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Nuvance Health - Norwalk
Florida
- University of Florida (UF) - Shands Cancer Center - Gainesville
Indiana
- Indiana University (IU) Melvin and Bren Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What NCT05023486 shows while recruiting
NCT05023486 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 1 condition, with Advanced or Metastatic Solid Tumor Malignancies appearing as the primary indexed condition, and to 3 interventions - of which NP-G2-044 Monotherapy is the first listed.
NCT05023486 lists 18 locations in 13 states (California, Arizona, Ohio).
Frequently Asked Questions
What is clinical trial NCT05023486 about?
NCT05023486 is a clinical study titled "NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies". Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
What is the current status of trial NCT05023486?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2021-12-07. Estimated completion is 2026-09-30.
What conditions does trial NCT05023486 study?
This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumor Malignancies.
What interventions are being tested in trial NCT05023486?
The interventions under investigation include: NP-G2-044 Monotherapy (DRUG), Anti-PD-1 Therapy (DRUG), NP-G2-044 Combination therapy (DRUG).
Who is sponsoring clinical trial NCT05023486?
This trial is sponsored by Novita Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023486 being conducted?
This trial has 18 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced or Metastatic Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05023486's enrollment target sits among peer trials
140 403rd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI